Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Gruenenthal
Gruenenthal
Activities:
Manufacturing
Research & Development
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Memel Biotech and Therabest collaborate to develop exosome-based cell therapies
The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates
The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Research & Development
Catalent and Grünenthal announce manufacturing collaboration
In this phase, Catalent supported Grünenthal with the development of a bioavailability enhanced formulation
Grünenthal appoints Gabriel Baertschi as Chairman and Chief Executive
He follows Prof. Dr Eric-Paul Paques who retires after 23 years with the company
Finance
Grünenthal Group agrees to buy Almirall's operations in Mexico
The deal is a key element of the German Group's strategy to strengthen its footprint in Latin America
Finance
Gruenenthal completes acquisition of Empresas Andromaco
Almost doubles sales in Latin America
Research & Development
Xention and Grünenthal sign research agreement
To focus on new drugs to treat chronic pain
Subscribe now